[go: up one dir, main page]

AR077846A1 - Metodo para disminuir los sintomas nasales asociado a la administracion de nicotina en la mucosa nasal - Google Patents

Metodo para disminuir los sintomas nasales asociado a la administracion de nicotina en la mucosa nasal

Info

Publication number
AR077846A1
AR077846A1 ARP100102937A ARP100102937A AR077846A1 AR 077846 A1 AR077846 A1 AR 077846A1 AR P100102937 A ARP100102937 A AR P100102937A AR P100102937 A ARP100102937 A AR P100102937A AR 077846 A1 AR077846 A1 AR 077846A1
Authority
AR
Argentina
Prior art keywords
nasal
symptoms associated
nicotine
decreasing
nasal mucosa
Prior art date
Application number
ARP100102937A
Other languages
English (en)
Inventor
Jorge Alberto Cassara
Julio Cesar Vega
Original Assignee
Pablo Cassara Srl Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pablo Cassara Srl Lab filed Critical Pablo Cassara Srl Lab
Publication of AR077846A1 publication Critical patent/AR077846A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion para administracion en la mucosa nasal de un sujeto que consta de una solucion de nicotina o una sal farmacéuticamente aceptable de la misma en un diluyente farmacéuticamente aceptable. La composicion posee una concentracion de nicotina inferior a 1,0 mg/ml. La composicion en sí ayuda a reducir el deseo de fumar tabaco. También disminuye los síntomas nasales asociados con el consumo de altas concentraciones de nicotina en la mucosa nasal.
ARP100102937A 2009-08-29 2010-08-11 Metodo para disminuir los sintomas nasales asociado a la administracion de nicotina en la mucosa nasal AR077846A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/550,355 US20110053988A1 (en) 2009-08-29 2009-08-29 Low-dose, non-irritating nicotine nasal composition to reduce the desire to smoke

Publications (1)

Publication Number Publication Date
AR077846A1 true AR077846A1 (es) 2011-09-28

Family

ID=43625770

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102937A AR077846A1 (es) 2009-08-29 2010-08-11 Metodo para disminuir los sintomas nasales asociado a la administracion de nicotina en la mucosa nasal

Country Status (4)

Country Link
US (2) US20110053988A1 (es)
AR (1) AR077846A1 (es)
BR (1) BRPI1015515A2 (es)
MX (1) MX2010009165A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011114094A1 (de) * 2011-09-21 2013-03-21 F. Holzer Gmbh Stimulierendes und belebendes Nasenspray und Nasentropfen
WO2020096686A2 (en) * 2018-09-05 2020-05-14 Sensory Cloud, Llc Formulations and compositions for ortho- and/or retro-nasal delivery and associated systems, methods and articles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
MA23588A1 (fr) * 1994-06-23 1995-12-31 Procter & Gamble Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme
US6596740B2 (en) * 2000-10-24 2003-07-22 Richard L. Jones Nicotine mucosal spray

Also Published As

Publication number Publication date
MX2010009165A (es) 2011-02-28
BRPI1015515A2 (pt) 2014-02-25
US20110053988A1 (en) 2011-03-03
US20120022114A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
EA201100896A1 (ru) Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение
AR060932A1 (es) Producto y su uso y elaboracion
CY1121939T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν νιτρωδες νατριο
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
NO20084987L (no) Belagt farmasoytisk produkt for intraoral avlevering av nikotin innbefattende trometamol som bufringsmiddel
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UA115648C2 (uk) Доставка терапевтичних агентів до цнс
BR112012013847A2 (pt) novos derivados de indolinona ciclopropano
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
UY30334A1 (es) Derivados de triazolopirazina
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
NO20072920L (no) Kombinasjon av metylxantinforbindelser og steroider for a behandle kroniske respirasjonssykdommer
PH12012500789A1 (en) Prolyl hydroxylase inhibitors
BRPI0922796A2 (pt) Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CR11418A (es) Trans-clomifeno para el sindrome metabolico
GT201200164A (es) "nuevos compuestos de espiropiperidina"
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
ECSP12011699A (es) Tableta
EA201290374A1 (ru) Аэрозольная композиция для copd
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
PL2244703T3 (pl) Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii

Legal Events

Date Code Title Description
FC Refusal